Table 9Results of other antiplatelet comparisons

StudyType of Study
N Analyzeda
Comparison
Quality
Outcome
Length of Followup
Results Reported by Authors
Horrocks, 199762

Patients with IC or CLI
RCT (open label)
N: 38
ASA or iloprost vs. no antiplatelet
Fair
Restenosis
Reocclusion

3 mo
Restenosis:
ASA 5, iloprost 0, placebo 3

Reocclusion:
ASA 0, iloprost 1, placebo 0
Minar, 199558

Patients with IC or CLI
RCT
N: 216
ASA 1000 mg vs. ASA 100 mg
Fair
Total mortality
Primary vessel patency

2 yr
Total mortality:
1000 mg ASA 14; 100 mg ASA 13

Primary vessel patency:
1000 mg ASA 62.5%
100 mg ASA 62.6%
a

Number of patients in the study arms of interest.

Abbreviations: ASA=acetylsalicylic acid (aspirin); CLI=critical limb ischemia; IC=intermittent claudication; LSM=least squares mean; mg=milligram; RCT=randomized controlled trial; yr=year/years.

Number of patients in the study arms of interest.

From: Results

Cover of Treatment Strategies for Patients With Peripheral Artery Disease
Treatment Strategies for Patients With Peripheral Artery Disease [Internet].
Comparative Effectiveness Reviews, No. 118.
Jones WS, Schmit KM, Vemulapalli S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.